| Name | BD750 |
| Description | BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in mouse and human T cells, respectively) |
| Animal Research | Female C57BL/6 mice (10 wks old, 19-21 g).Dosage with 20 μM, and administration:IV, treated DC on d 7, 11 and 15 post the first PTX injection (dpi 7, 11 and 15)[1]. |
| In vitro | Following BD750 treatment, LPS-induced maturation of DC, allogeneic T cell proliferation, Th1 and Th17 cell functional differentiation, the STAT5 and AKT activation were determined.?The effect of tolDC loaded with antigen peptide on the development and severity of EAE and their splenic Th1 and Th17 cell responses were determined.?In comparison with LPS-induced mature DC (mDC), BD750 treatment induced tolDC with lower expression levels of costimulatory molecules and pro-inflammatory cytokines and lower levels of STAT5 phosphorylation.?TolDC inhibited allogeneic T cell proliferation and reduced Th1 and Th17 responses[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 27.5 mg/mL (101.35 mM)
|
| Keywords | Immunosuppressant | JAK | BD-750 | BD 750 | cell | Janus kinase | inhibit | STAT | Inhibitor | BD750 |
| Inhibitors Related | Delgocitinib | Ruxolitinib | Nifuroxazide | Balsalazide sodium hydrate | Tofacitinib Citrate | Fludarabine | Niclosamide | Ruxolitinib phosphate | CASIN | Diosgenin | Niclosamide olamine | Artesunate |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Reprogramming Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library |
United States
